ABOS
Acumen Pharmaceuticals, Inc.
$2.19
+0.92%
$156.7M
No data for this timeframe.
Vol
Market Cap$156.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders7 funds
Inst. Value$9.8M
Inst. Activity0 buys / 2 sells
Insider Activity0B / 1S
Insider Net $-$6.8K
Reddit Sentiment60° Warm
SEC Reports3
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001576885·Prev Close $2.17
Recent Activity
Jun 3, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. sold 35,500 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. sold 53,250 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
Drapkin Kimberlee C sold 35,500 shares
Director @ $0.00 ($0.00)
May 12, 2026
SEC
Acumen Pharmaceuticals reported Q1 2026 results with a net loss of $20.7M ($0.33/share), narrower than the $28.8M loss (
8-K — Impact 3/10
May 12, 2026
SEC
Acumen Pharmaceuticals reported Q1 2026 EPS of -$0.33 (GAAP) vs consensus of -$0.46, a 28.3% beat, with net loss narrowi
PRESS-RELEASE — Impact 5/10
May 12, 2026
earnings
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
<p>NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?
Mar 26, 2026
SEC
Acumen Pharmaceuticals filed an S-3 shelf registration to register the resale of up to 10,833,331 shares of common stock
S-3 — Impact 5/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
423,100 shares ($892.7K)
Price Targets
$7.40
+237.9% upside
Strong Buy
Current $2.19
Low $4.00
Median $8.00
High $10.00
5 analysts
$4.00
$10.00
Analyst Ratings
6Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 26, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 16, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Jan 27, 2026 | BTIG | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.41 ▲ +11.9% | $-0.49 — $-0.32 | 40% YoY | 3 |
| Next Q | $-0.42 ▲ +3.8% | $-0.51 — $-0.33 | 4% YoY | 3 |
| Current FY | $-1.58 ▲ +13.7% | $-1.76 — $-1.32 | 21% YoY | 3 |
| Next FY | $-1.51 ▼ -8.2% | $-1.68 — $-1.35 | 5% YoY | 3 |
Latest Reports
NEUTRAL
8-K
3/10
Acumen Pharmaceuticals reported Q1 2026 results with a net loss of $20.7M ($0.33/share), narrower than the $28.8M loss (
May 12, 2026
NEUTRAL
PRESS-RELEASE
5/10
Acumen Pharmaceuticals reported Q1 2026 EPS of -$0.33 (GAAP) vs consensus of -$0.46, a 28.3% beat, with net loss narrowi
May 12, 2026
MIXED
Press
6/10
Acumen Pharmaceuticals reported its 2025 financial results, showing increased R&D spending and a wider net loss, while m
Mar 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $4.3M | — |
| VANGUARD GROUP INC | $3.5M | — |
| RENAISSANCE TECHNOLOGIES LLC | $892.7K | TRIM |
| BANK OF AMERICA CORP | $506.7K | ADD |
| MORGAN STANLEY | $352.2K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | RA CAPITAL | A | $0.00 |
| Jun 3, 2026 | RA CAPITAL | A | $0.00 |
| Jun 3, 2026 | Drapkin Kimberlee | A | $0.00 |
| Jun 3, 2026 | Drapkin Kimberlee | A | $0.00 |
| Jun 3, 2026 | Fountain Nathan | A | $0.00 |
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
7 institutional holders with $9.8M total value (4,661,747 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, RENAISSANCE. Net selling activity: 2 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 2,027,497 | $4.3M | 43.5% | — |
| 2 | VANGUARD GROUP INC | 1,653,772 | $3.5M | 35.5% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 423,100 | $892.7K | 9.1% | TRIM -27.6% |
| 4 | BANK OF AMERICA CORP /DE/ | 240,152 | $506.7K | 5.2% | ADD +45.4% |
| 5 | MORGAN STANLEY | 166,905 | $352.2K | 3.6% | TRIM -42.7% |
| 6 | TWO SIGMA INVESTMENTS, LP | 143,221 | $302.2K | 3.1% | TRIM -28.2% |
| 7 | WELLS FARGO & COMPANY/MN | 7,100 | $15.0K | 0.2% | NEAR_EXIT -75.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 584,292 | 423,100 | -27.6% | $892.7K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 199,446 | 143,221 | -28.2% | $302.2K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 246,588 | 584,292 | +137.0% | $999.1K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 147,009 | 213,729 | +45.4% | $365.5K | 2025-Q3 |
| UBS Group AG | TRIM | 94,422 | 30,841 | -67.3% | $52.7K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 27,678 | 6,825 | -75.3% | $7.9K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 116,902 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | TRIM | 266,216 | 152,636 | -42.7% | $167.9K | 2025-Q1 |
| UBS Group AG | DOUBLED | 22,751 | 141,492 | +521.9% | $243.4K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 87,809 | 239,200 | +172.4% | $593.2K | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 108,743 | — | $269.7K | 2024-Q3 |
9 unique insiders with 1 transactions. Net insider value: -$6.8K ($0.00 bought, $6.8K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | A | 35,500 | $0.00 | $0.00 |
| Jun 3, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | A | 53,250 | $0.00 | $0.00 |
| Jun 3, 2026 | Drapkin Kimberlee C | Director | A | 35,500 | $0.00 | $0.00 |
| Jun 3, 2026 | Drapkin Kimberlee C | Director | A | 53,250 | $0.00 | $0.00 |
| Jun 3, 2026 | Fountain Nathan B | Director | A | 35,500 | $0.00 | $0.00 |
| Jun 3, 2026 | Fountain Nathan B | Director | A | 53,250 | $0.00 | $0.00 |
| Jun 3, 2026 | Stalfort John A III | Director | A | 35,500 | $0.00 | $0.00 |
| Jun 3, 2026 | Porter Derrell | Director | A | 53,250 | $0.00 | $0.00 |
| Jun 3, 2026 | Porter Derrell | Director | A | 35,500 | $0.00 | $0.00 |
| Jun 3, 2026 | Stoppel Laura | Director | A | 35,500 | $0.00 | $0.00 |
| Jun 3, 2026 | Ives Jeffrey L. | Director | A | 35,500 | $0.00 | $0.00 |
| Jun 3, 2026 | Stalfort John A III | Director | A | 53,250 | $0.00 | $0.00 |
| Jun 3, 2026 | Golumbeski George | Director | A | 53,250 | $0.00 | $0.00 |
| Jun 3, 2026 | Golumbeski George | Director | A | 35,500 | $0.00 | $0.00 |
| Jun 3, 2026 | Ives Jeffrey L. | Director | A | 53,250 | $0.00 | $0.00 |
| Jun 3, 2026 | Stoppel Laura | Director | A | 53,250 | $0.00 | $0.00 |
| Mar 16, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | A | 6,060,606 | $3.30 | $20.0M |
| Mar 6, 2026 | Meisner Derek M | Chief Legal Officer & Corp Sec | M | 2,090 | $1.85 | $3.9K |
| Mar 6, 2026 | Meisner Derek M | Chief Legal Officer & Corp Sec | SELL | 2,090 | $3.26 | $6.8K |
| Mar 6, 2026 | Meisner Derek M | Chief Legal Officer & Corp Sec | M | 2,090 | $0.00 | $0.00 |
| Feb 27, 2026 | Meisner Derek M | Chief Legal Officer & Corp Sec | M | 9,406 | $1.85 | $17.4K |
| Feb 27, 2026 | Meisner Derek M | Chief Legal Officer & Corp Sec | M | 9,406 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.3/10.
NEUTRAL
8-K
3/10
Acumen Pharmaceuticals reported Q1 2026 results with a net loss of $20.7M ($0.33/share), narrower th
May 12, 2026
NEUTRAL
PRESS-RELEASE
5/10
Acumen Pharmaceuticals reported Q1 2026 EPS of -$0.33 (GAAP) vs consensus of -$0.46, a 28.3% beat, w
May 12, 2026
NEUTRAL
S-3
5/10
Acumen Pharmaceuticals filed an S-3 shelf registration to register the resale of up to 10,833,331 sh
Mar 26, 2026
MIXED
6/10
Acumen Pharmaceuticals reported its 2025 financial results, showing increased R&D spending and a wid
Mar 26, 2026
NEUTRAL
4/10
Acumen Pharmaceuticals announced it will report its Q4 and full-year 2025 financial results on March
Mar 19, 2026
MIXED
6/10
Acumen Pharmaceuticals (ABOS) announced a $35.75 million private placement at $3.30 per share, led b
Mar 16, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 6 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.40 mean target
+237.9% upside
Strong Buy (1.00)
$4.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $2.19 |
| Target Low | $4.00 |
| Target Mean | $7.40 |
| Target Median | $8.00 |
| Target High | $10.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.41 | $-0.49 | $-0.32 | 40.4% | +11.9% | — | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.42 | $-0.51 | $-0.33 | 3.8% | +3.8% | — | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-1.58 | $-1.76 | $-1.32 | 20.8% | +13.7% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-1.51 | $-1.68 | $-1.35 | 4.9% | -8.2% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.405 | |
| 7d ago | $-0.422 | +0.017 |
| 30d ago | $-0.460 | +0.055 |
| 60d ago | $-0.460 | +0.055 |
| 90d ago | $-0.460 | +0.055 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 26, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 16, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 27, 2026 | BTIG | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 12, 2026
earnings
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
<p>NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=3zunWdg53cpXYGJOymmNegYsexqjb5FdCrmk5Czf7zaFc
May 12, 2026
earnings_calendar
ABOS Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
earnings_calendar
ABOS Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
other
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
<p align="left">NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=BHonimD9qP4wrg7AG5_ifTx2JSDqsy92
May 5, 2026
earnings
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
<p>NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=wWeyqc9r5OEatBpFhZ1VtUZJyrRBpFS8XGzntVfkMvUgV
Mar 26, 2026
earnings
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
<p>NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=FfNp0mqT1Cqp0dSmsZb6xAiEgOXHXEofxnY_aoDHbI
Mar 26, 2026
earnings_calendar
ABOS Q4 2025 Earnings After Market Close — 2026-03-26
Mar 19, 2026
earnings
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
<p>NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=QY6bOSvufPuHQcHM7jPVjF6XaA3MS7AyrLMbEB7MCJw
Mar 16, 2026
offering
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
<p>NEWTON, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=B43QySpFz4N8XMLyVUtTXsRSjG58xnCJBQN04wZcWL
Mar 10, 2026
other
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
<p>NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=miSn7hFmX2ega561eKdQK2XZ2_4AXkf35nv8tNKbXvP